Opportunity ID: 203037

General Information

Document Type:: Grants Notice
Funding Opportunity Number:: RFA-HL-13-027
Funding Opportunity Title:: Functional Assays to Screen Genomic Hits (R21/R33)
Opportunity Category:: Discretionary
Opportunity Category Explanation::
Funding Instrument Type::
Category of Funding Activity:: Health
Category Explanation::
Expected Number of Awards::
Assistance Listings Number(s):: 93.233 — National Center on Sleep Disorders Research
Cost Sharing or Matching Requirement:: No
Version:: Synopsis 2
Posted Date:: Oct 02, 2012
Last Updated Date:: Oct 21, 2013
Original Closing Date for Applications:: Oct 23, 2013
Current Closing Date for Applications:: Nov 01, 2013
Archive Date:: Dec 01, 2013
Estimated Total Program Funding:: $ 2,500,000
Award Ceiling:: $
Award Floor:: $

Eligibility

Eligible Applicants:: For profit organizations other than small businesses
Additional Information on Eligibility:: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name:: National Institutes of Health
Description:: This funding opportunity announcement (FOA) issued by National Heart, Lung, and Blood Institute (NHLBI) invites applications to conduct functional analyses of identified genetic variations related to heart, lung, blood and sleep phenotypes, using amenable in vitro or animal model systems. Exploratory/Developmental Phased Innovation (R21/R33) grant applications should identify and justify the genetic variants that they propose to test for functionality, the phenotype(s) the variants are associated with, and the functional measures that will be used to validate them. This FOA provides support for two years (R21 phase) for research planning activities and feasibility studies, followed by possible transition of up to three years of expanded research support (R33 phase). The total project period for an application submitted in response to this FOA may not exceed five years. This FOA requires measurable R21 milestones.
Link to Additional Information::
Grantor Contact Information:: If you have difficulty accessing the full announcement electronically, please contact:

Version History

Version Modification Description Updated Date
Synopsis 2 Modified Archive Date based on new Expiration Date, per NOT-OD-14-003. Oct 21, 2013
Synopsis 1

Package

Below are CLOSED Opportunity Package(s) no longer available for this Funding Opportunity:

Package No: 1

Package No: 2

Packages

Assistance Listings Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions Who Can Apply:
ADOBE-FORMS-B2 Adobe-Forms-B2 PKG00148523 Dec 23, 2012 Sep 24, 2013 View Grants Info Organization Applicants

Assistance Listings Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions Who Can Apply:
FORMS-C Use for due dates after 9/24/2013. PKG00181209 Sep 16, 2013 Nov 01, 2013 View eRA Commons Help Desk Organization Applicants